Author: Sun Myint A.; Sripadam R.; Dhadda A.; Rao C.; Pierre Gerard J.
Abstract: We read with interest the 5-year oncological outcomes for GRECCAR 2, including
local recurrence, metastatic disease, and survival. 1 GRECCAR 2 is the first
multicentre, randomised trial to compare local excision with total mesorectal
excision (TME) in downstaged low rectal cancer. The oncological outcomes are
comparable in both arms, suggesting that patients with cT2cT3 tumours can be
offered local excision instead of TME surgery. This has major implications in
the way we consent patients with rectal cancer. More importantly, could this be
a game changer in rectal cancer management?
